Annovis Bio (NYSE:ANVS - Free Report) had its price target lowered by HC Wainwright from $30.00 to $12.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Annovis Bio's Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.52) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.66) EPS.
Other research analysts have also recently issued research reports about the company. Canaccord Genuity Group cut their price target on Annovis Bio from $26.00 to $17.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. D. Boral Capital restated a "hold" rating on shares of Annovis Bio in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $30.25.
View Our Latest Stock Report on ANVS
Annovis Bio Price Performance
NYSE ANVS traded up $0.15 during trading hours on Monday, hitting $2.95. The company had a trading volume of 295,622 shares, compared to its average volume of 738,037. The firm's 50 day moving average is $1.83 and its 200 day moving average is $3.10. The company has a market capitalization of $57.48 million, a price-to-earnings ratio of -0.66 and a beta of 1.62. Annovis Bio has a fifty-two week low of $1.11 and a fifty-two week high of $17.88.
Annovis Bio (NYSE:ANVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.15. On average, equities analysts anticipate that Annovis Bio will post -2.19 EPS for the current year.
Hedge Funds Weigh In On Annovis Bio
Several large investors have recently modified their holdings of the stock. Lokken Investment Group LLC increased its holdings in Annovis Bio by 60.3% in the first quarter. Lokken Investment Group LLC now owns 29,235 shares of the company's stock valued at $44,000 after buying an additional 11,000 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Annovis Bio in the 4th quarter valued at approximately $55,000. Warberg Asset Management LLC bought a new stake in shares of Annovis Bio in the 1st quarter valued at approximately $58,000. XTX Topco Ltd acquired a new stake in shares of Annovis Bio during the 4th quarter valued at approximately $59,000. Finally, Atria Wealth Solutions Inc. bought a new position in Annovis Bio during the fourth quarter worth $65,000. Institutional investors own 15.83% of the company's stock.
About Annovis Bio
(
Get Free Report)
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Read More
Before you consider Annovis Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annovis Bio wasn't on the list.
While Annovis Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
